The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM).
Ryan J. Sullivan
No relevant relationships to disclose
Nageatte Ibrahim
No relevant relationships to disclose
Donald P. Lawrence
No relevant relationships to disclose
Julie Aldridge
No relevant relationships to disclose
F. Stephen Hodi
No relevant relationships to disclose
Keith Flaherty
No relevant relationships to disclose
Christine Conley
No relevant relationships to disclose
Sarah DeNoble
No relevant relationships to disclose
James Walter Mier
No relevant relationships to disclose
Daniel C. Cho
No relevant relationships to disclose
Michael B. Atkins
No relevant relationships to disclose
David F. McDermott
No relevant relationships to disclose